Safety assessment of intradiscal gene transfer: a pilot study

BackgroundSeveral recent in vitro and in vivo studies have reported the beneficial properties of gene delivery of therapeutic factors to the intervertebral disc, as a potential treatment strategy for degenerative disc disease; however, to date, no studies have assessed the safety and toxicity of the practical application of this treatment modality.PurposeTo assess the safety of inappropriately dosed or misdirected gene delivery to the spinal column in an in vivo model.Study designThe potential toxicity of gene therapy to the spinal column was assessed in this pilot study by monitoring clinical and histological changes in the spinal cord after intradural injections of an adenoviral vector containing the complementary deoxyribonucleic acid (cDNA) for potentially therapeutic factors in the treatment of degenerative disc disease.MethodsFourteen New Zealand White rabbits were divided into experimental groups to receive an intradural injection (<10 μL) of saline alone or saline in combination with recombinant transforming growth factor ß1 (TGF-ß1) or an adenoviral vector containing the cDNA for either TGF-ß1 (at previously established therapeutic or elevated concentrations) or bone morphogenic protein-2 (BMP-2). Animals were monitored clinically and spinal cords were harvested for histological analysis.ResultsNo neurological deficits developed in any of the animals receiving injections of saline alone or saline in combination with the therapeutic dose of Ad-TGF-ß1, Ad-BMP-2, or with recombinant TGF-ß1. However, animals receiving a higher concentration of Ad-TGF-ß1 developed bilateral lower extremity paralysis with significant histological changes.ConclusionsInappropriately dosed or directed gene delivery to the spinal column may result in significant complications. However, with appropriate dosing, a therapeutic window may exist where the potential benefits of gene therapy in the treatment of degenerative disc disease outweigh its risks.